abstract |
The present disclosure relates to methods or dosing regimens comprising a proteasome inhibitor of formula (I), or a pharmaceutically acceptable salt thereof, n nfor treating cancer, or preventing cancer recurrence or progression; wherein ring A, Z 1 and Z 2 are as defined herein. |